Preclinical and early clinical studies with BW 1370U87, a reversible competitive MAO-A inhibitor.
Div. of Pharmacology Burroughs Wellcome Co., Research Triangle Park, NC 27709.
H L
HL
White
J A
JA
Ascher
D000818:Animals; D001794:Blood Pressure / Q000187:drug effects; D001923:Brain Chemistry / Q000187:drug effects; D004285:Dogs; D004341:Drug Evaluation; D006571:Heterocyclic Compounds / Q000009:adverse effects / Q000494:pharmacology*; D006801:Humans; D008996:Monoamine Oxidase Inhibitors / Q000009:adverse effects / Q000494:pharmacology*; D018377:Neurotransmitter Agents / Q000378:metabolism; D051381:Rats; D014439:Tyramine / Q000494:pharmacology
D006571:Heterocyclic Compounds; D008996:Monoamine Oxidase Inhibitors; D018377:Neurotransmitter Agents; C076100:1-ethylphenoxathiin 10,10-dioxide; D014439:Tyramine